A 54-year-old woman with a 10-year history of rheumatoid arthritis has persistent moderate disease activity despite optimal methotrexate therapy. She has no contraindications to biologic agents. According to Canadian Rheumatology Association recommendations, what is the most appropriate next pharmacologic step?